Ubiquitin protein ligase E3A (UBE3A) (UBE3A)

The Ubiquitin protein ligase E3A (UBE3A) genomic locus, located on chromosome 15q11.2-q13, is a critical target for neurodevelopmental therapies (NIH, 2023). In the brain, UBE3A is regulated by genomic imprinting, where the maternal allele is active and the paternal allele is silenced by the UBE3A antisense transcript (UBE3A-ATS) (UniProt, 2024). The UBE3A protein functions as an E3 ubiquitin ligase, mediating the degradation of proteins involved in synaptic plasticity and cellular signaling (PubMed, 2015). Loss of maternal UBE3A expression causes Angelman syndrome, a disorder characterized by severe developmental delays and seizures (GeneReviews, 2021). Conversely, overexpression or duplication of this locus is a known genetic cause of Dup15q syndrome and certain forms of autism (Nature Communications, 2020). Therapeutic intervention primarily focuses on unsilencing the paternal allele using antisense oligonucleotides (ASOs) that target and degrade the UBE3A-ATS (Nature, 2021). Investigational drugs like GTX-102 and Rugonersen aim to restore UBE3A protein levels in neurons to alleviate the symptoms of Angelman syndrome (ClinicalTrials.gov, 2023). This target represents a prime example of epigenetic modulation in precision medicine, requiring careful titration to avoid the risks associated with protein overexpression.

Other names

E6APE6-associated proteinHPVE6AAngelman syndrome chromosome regionEPVE6A15q11.2-q13 locusUBE3A-ATSUBE3A genomic locus

Unsilencing of the paternal UBE3A allele via antisense oligonucleotide-mediated degradation of the UBE3A antisense transcript (UBE3A-ATS).